The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lysantin     N,N-dimethyl-2-[(2- methylphenyl)-phenyl...

Synonyms: Antiflex, Biorphen, Disipal, Mefenamine, Mephenamine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Disipal


Psychiatry related information on Disipal


High impact information on Disipal


Chemical compound and disease context of Disipal


Biological context of Disipal


Anatomical context of Disipal


Associations of Disipal with other chemical compounds


Gene context of Disipal


Analytical, diagnostic and therapeutic context of Disipal


  1. Deaths after overdoses of orphenadrine. Millar, W.M. Lancet (1977) [Pubmed]
  2. Non-sustained ventricular tachycardia due to low-dose orphenadrine. Dilaveris, P., Pantazis, A., Vlasseros, J., Gialafos, J. Am. J. Med. (2001) [Pubmed]
  3. An extrapyramidal syndrome after lithium therapy. Tyrer, P., Alexander, M.S., Regan, A., Lee, I. The British journal of psychiatry : the journal of mental science. (1980) [Pubmed]
  4. In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity. Sureda, F.X., Gabriel, C., Pallàs, M., Adan, J., Martínez, J.M., Escubedo, E., Camarasa, J., Camins, A. Neuropharmacology (1999) [Pubmed]
  5. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Pubill, D., Verdaguer, E., Canudas, A.M., Sureda, F.X., Escubedo, E., Camarasa, J., Pallàs, M., Camins, A. Br. J. Pharmacol. (2001) [Pubmed]
  6. Letter: Restless legs: precipitated by beta blockers, relieved by orphenadrine. Morgan, L.K. Med. J. Aust. (1975) [Pubmed]
  7. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Reidy, G.F., Mehta, I., Murray, M. Mol. Pharmacol. (1989) [Pubmed]
  8. Examination of purported probes of human CYP2B6. Ekins, S., VandenBranden, M., Ring, B.J., Wrighton, S.A. Pharmacogenetics (1997) [Pubmed]
  9. Alkylation of cellular macromolecules and target specificity of carcinogenic nitrosodialkylamines: metabolic activation by cytochromes P450 2B1 and 2E1. Shu, L., Hollenberg, P.F. Carcinogenesis (1997) [Pubmed]
  10. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Bersani, G., Grispini, A., Marini, S., Pasini, A., Valducci, M., Ciani, N. Clinical neuropharmacology. (1990) [Pubmed]
  11. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Henderson, R.A., Lane, S., Henry, J.A. Human & experimental toxicology. (1991) [Pubmed]
  12. Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa. Bassi, S., Albizzati, M.G., Calloni, E., Sbacchi, M., Frattola, L. The British journal of clinical practice. (1986) [Pubmed]
  13. A controlled study of the effect of orphenadrine hydrochloride (Disipal) on vertigo in patients with spontaneous vestibular disease. Camarda, V., Di Carlo, A. The British journal of clinical practice. (1982) [Pubmed]
  14. Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from capsaicin-irritated skin in healthy volunteers. Schaffler, K., Reitmeir, P. Arzneimittel-Forschung. (2004) [Pubmed]
  15. Upregulation of cytochromes P450 2B in rat liver by orphenadrine. Murray, M., Fiala-Beer, E., Sutton, D. Br. J. Pharmacol. (2003) [Pubmed]
  16. Human liver CYP2B6-catalyzed hydroxylation of RP 73401. Stevens, J.C., White, R.B., Hsu, S.H., Martinet, M. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  17. Relationship between molecular structure and cytochrome P450-metabolic intermediate complex formation, studied with orphenadrine analogues. Bast, A., Savenije-Chapel, E.M., Noordhoek, J. Journal of pharmaceutical sciences. (1984) [Pubmed]
  18. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Labout, J.J., Thijssen, C., Keijser, G.G., Hespe, W. Eur. J. Clin. Pharmacol. (1982) [Pubmed]
  19. Effects of anticholinergic agents on the excitability of the blink reflex in Meige syndrome. Rossi, B., Vignocchi, G., Siciliano, G., Risaliti, R. Eur. Neurol. (1989) [Pubmed]
  20. Assessment of the adrenergic effects of orphenadrine in rat vas deferens. Pubill, D., Canudas, A.M., Pallàs, M., Sureda, F.X., Escubedo, E., Camins, A., Camarasa, J. J. Pharm. Pharmacol. (1999) [Pubmed]
  21. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. Kornhuber, J., Parsons, C.G., Hartmann, S., Retz, W., Kamolz, S., Thome, J., Riederer, P. J. Neural Transm. Gen. Sect. (1995) [Pubmed]
  22. Orphenadrine (Disipal), serum thyroxine and thyroid function. Wiersinga, W.M., Fabius, A.J., Touber, J.L. Acta Endocrinol. (1977) [Pubmed]
  23. Comparison of depressant actions of orphenadrine and diazepam on hypertonic skeletal muscle activity. Williamson, H.E. Archives internationales de pharmacodynamie et de thérapie. (1989) [Pubmed]
  24. Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine. Biella, G.E., Groppetti, A., Novelli, A., Fernández-Sánchez, M.T., Manfredi, B., Sotgiu, M.L. J. Neurotrauma (2003) [Pubmed]
  25. Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study. Pigache, R.M. Schizophr. Res. (1993) [Pubmed]
  26. Propofol metabolism is enhanced after repetitive ketamine administration in rats: the role of cytochrome P-450 2B induction. Chan, W.H., Chen, T.L., Chen, R.M., Sun, W.Z., Ueng, T.H. British journal of anaesthesia. (2006) [Pubmed]
  27. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Guo, Z., Raeissi, S., White, R.B., Stevens, J.C. Drug Metab. Dispos. (1997) [Pubmed]
  28. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Oda, Y., Hamaoka, N., Hiroi, T., Imaoka, S., Hase, I., Tanaka, K., Funae, Y., Ishizaki, T., Asada, A. British journal of clinical pharmacology. (2001) [Pubmed]
  29. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Heyn, H., White, R.B., Stevens, J.C. Drug Metab. Dispos. (1996) [Pubmed]
  30. Postoperative analgesia using papaveretum and orphenadrine. A preliminary trial. Fry, E.N. Anaesthesia. (1979) [Pubmed]
  31. Effect of central muscle relaxants on single-dose pharmacokinetics of peroral paracetamol in man. Saano, V., Elo, H.A., Paronen, P. International journal of clinical pharmacology, therapy, and toxicology. (1990) [Pubmed]
  32. The influence of physostigmine on respiratory and circulatory changes caused by overdoses of orphenadrine or imipramine in the rat. Zandberg, P., Sangster, B. Acta pharmacologica et toxicologica. (1982) [Pubmed]
  33. Death caused by orphenadine poisoning. Sørensen, H.C., Munk-Jørgensen, P. Z. Rechtsmed. (1986) [Pubmed]
  34. Cardiotoxicity from orphenadrine intoxication in humans. Malizia, E., Sarcinelli, L., Pascarella, M., Ambrosini, M., Smeriglio, M., Russo, A. Arch. Toxicol. Suppl. (1980) [Pubmed]
WikiGenes - Universities